Summary of the Conference Call for 石四药集团 (Sihuan Pharmaceutical Group) Company Overview - **Company**: Sihuan Pharmaceutical Group - **Date of Call**: March 27, 2026 Key Financial Performance - **2025 Net Profit**: HKD 471 million, a decrease of 55.6% year-on-year, but the decline is less severe compared to the mid-year results [2][3] - **Sales Revenue**: Approximately HKD 4.165 billion, down 27.8% year-on-year; in RMB, it is about CNY 3.812 billion [3] - **Gross Margin**: Approximately 41.6%, down 8.8 percentage points year-on-year due to increased revenue share from centralized procurement and price declines in existing products [3] - **Dividend**: Maintained at HKD 0.08 per share, with a payout ratio close to 50% [3] - **Cash and Cash Equivalents**: Approximately HKD 1.69 billion at the end of 2025, an increase of HKD 433 million from the previous year [3] Business Segments and Growth Strategies Intravenous Solutions - **2026 Sales Target**: 1.85 billion bags (+20% growth) driven by the replacement of plastic bottles with upright bags and increased procurement [2][6] - **2025 Performance**: Sales volume of 1.536 billion bags, down 24.5%; sales revenue of HKD 2.485 billion, down 33.5% [6] Export Business - **2025 Export Growth**: Formulations export revenue increased by 35%, targeting HKD 300-350 million in 2026 [2][5] - **Packaging Materials**: Expected to double in growth, with significant market entry into Southeast Asia, South America, and the Middle East [5] Centralized Procurement - **Market Share**: Significant advantages in centralized procurement, with 12 products won in the 11th batch and plans to participate in 46 products in the 12th batch [2][4] Active Pharmaceutical Ingredients (APIs) - **Cost Advantage**: Self-produced calcium chloride and magnesium chloride at costs significantly lower than market prices (1/7 to 1/50) [2][11] - **2026 Outlook**: Expected recovery in business performance [2][11] Innovative Drugs - **Clinical Trials**: Plans to submit for Phase I clinical trials for pulmonary hypertension and epilepsy drugs by the end of 2026 [2][12] - **Partnerships**: Exclusive authorization for a sugar-free peritoneal dialysis solution from a Swiss company [2][17] Market Dynamics and Competitive Landscape - **Price Trends**: Continuous price decline in intravenous products, with a recent stabilization and expected price increases due to rising raw material costs [21][22] - **Market Share Concentration**: Centralized procurement is leading to increased market share for top-tier suppliers [22][23] Future Outlook - **2026 Goals**: Targeting 20% growth in intravenous solutions, with a focus on specialized products rather than standard saline solutions [15][22] - **Innovation Focus**: Plans to submit 2-3 Phase I clinical projects annually, leveraging AI for drug discovery [15][17] - **Export Revenue Target**: Expected formulation export revenue of HKD 300-350 million in 2026, with potential for further growth [17][18] Conclusion - **Management Confidence**: Despite recent challenges, the company is optimistic about returning to 2020 performance levels within two years, emphasizing shareholder value and strategic growth initiatives [24]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 4.20 [1][9]. Core Views - The report highlights a recovery in the large-volume infusion and ampoule segments over the next 26 years, with high growth expected in oral formulations and an accelerated innovation transformation [1][5]. - The company reported a revenue of HKD 4.165 billion for 2025, a decrease of 27.8% year-on-year, and a net profit of HKD 470 million, down 55.6% year-on-year, which aligns with previous performance forecasts [1][5]. - The decline in revenue and profit is attributed to the increased proportion of products subject to volume-based procurement, a drop in unit prices for basic infusions and ampoules, and weak demand for raw materials [5][6]. Summary by Sections Financial Performance - For 2025, the company’s revenue is projected at HKD 4.165 billion, with a year-on-year decline of 27.85%. The net profit is expected to be HKD 470 million, reflecting a 55.65% decrease [4][5]. - The earnings per share (EPS) for 2025 is estimated at HKD 0.16, with projections for 2026, 2027, and 2028 at HKD 0.20, HKD 0.26, and HKD 0.32 respectively [4][9]. Segment Analysis - **Large-volume Infusions**: Revenue for 2025 is expected to be HKD 2.49 billion, down 33.5% year-on-year, primarily due to decreased sales volume and average selling price (ASP) [6]. - **Raw Materials**: The raw material segment is projected to generate HKD 680 million in 2025, a decline of 14% year-on-year, with expectations for recovery in 2026 driven by improved demand and pricing [7]. - **Oral Formulations**: Revenue for oral formulations is expected to be HKD 455 million in 2025, with a 15% increase in sales volume, driven by new product approvals [8]. Future Outlook - The report anticipates a recovery in 2026, with profit growth potentially reaching nearly 30%, supported by structural optimization in large-volume infusions, increased export ratios for formulations and raw materials, and a rebound in prices [5][6][8]. - The company is actively advancing its innovation pipeline, with a focus on new drug development, including several promising candidates in clinical trials [8].

Market Overview - The Asia-Pacific stock markets experienced a collective adjustment, with A-shares falling over 1% and the Shanghai Composite Index closing at 3889.08 points, down 1.09% [1][2] - The Hong Kong stock market also saw significant declines, with the Hang Seng Index dropping 1.89% to 24856.43 points and the Hang Seng Tech Index falling 3.28% [2][3] - The Nikkei 225 Index in Japan decreased by 0.27%, while the South Korean Composite Index fell by 3.22% [3][4] Oil Prices - International oil prices rose again, with ICE Brent crude reaching over $100 per barrel, currently reported at $99.66 per barrel, and WTI crude above $90 per barrel [5][6] - The increase in oil prices is attributed to geopolitical tensions, particularly the recent drone attack on a Turkish oil tanker in the Black Sea, which has raised concerns about supply disruptions [6] Pharmaceutical Sector - The raw material pharmaceutical stocks saw a strong rally, with companies like Meinuohua and Sitai Li hitting the daily limit, and Hongyuan Pharmaceutical rising approximately 8% [8] - The price increase in chemical products, driven by rising oil prices and higher energy costs, is expected to lead to a price hike in raw pharmaceutical materials, benefiting the sector [11] Lithium Battery Sector - The lithium battery concept stocks showed active trading, with Haike Xinyuan rising over 16% and Zhongrui Co. increasing by over 10% [13][14] - Zimbabwe's extended ban on lithium exports is expected to impact global supply, as the country is a significant source of lithium for China, potentially leading to price increases in lithium products [15] Company Specifics - Huadian Liaoning Energy's stock experienced a significant rise, achieving a 9-day consecutive limit up, but closed with a 6.47% increase amid concerns about stock price volatility [17][19] - The company has confirmed that its production and operational activities remain normal, with no significant changes in market conditions or internal operations [19]

Group 1: Company Strategy and Business Focus - The company is committed to focusing on its core business, emphasizing the "big health" development strategy in pharmaceuticals and healthcare [2] - In pharmaceuticals, the company aims to enhance its integrated development model, covering raw materials, formulations, functional skincare products, and skin health management [2][3] - The healthcare segment includes basic medical care, rehabilitation, and longevity services, creating a comprehensive health ecosystem for customers [2][4] Group 2: Pharmaceutical Business Overview - The pharmaceutical business involves the research, production, and sales of drug formulations and raw materials, with a focus on skin, anti-infection, and anti-tumor products [3] - The company has three raw material production bases, ensuring a stable supply of core products and establishing long-term partnerships with international pharmaceutical companies [3] - The company holds a 13.2% stake in a gene therapy company, making it the third-largest shareholder [3] Group 3: Healthcare Services - The healthcare services include basic medical treatment, rehabilitation, and health management, providing integrated services to improve patient health and longevity [4][5] - The company operates various medical institutions that collaborate on resources, technology, and training to enhance service quality [7] Group 4: Tourism Business - The tourism segment includes operations in scenic area transportation, hotel management, and tourism performances, primarily in five major 5A scenic spots [9] - The company aims to enhance its core competitiveness and improve management levels across its business segments, including tourism [9] Group 5: Financial Performance Projections - For 2025, the company expects a net profit attributable to shareholders between 66 million and 73 million, representing a year-on-year growth of 320.74% to 344.16% [9] - The net profit after excluding non-recurring gains is projected to be between 60 million and 67 million, indicating a growth of 277.59% to 298.31% compared to the previous year [9]

Investment Rating - The report suggests a focus on the pharmaceutical raw materials sector and the medical consumables sector, particularly the nitrile gloves market, indicating potential for price increases and profit elasticity [6][22]. Core Insights - The pharmaceutical raw materials sector is experiencing significant price increases due to rising chemical product costs, which are expected to be passed down the supply chain, leading to potential price hikes in raw materials [2][12]. - The medical consumables sector, specifically nitrile gloves, is characterized by high barriers to entry and stable supply dynamics, with a potential for price recovery due to rising raw material costs and geopolitical tensions affecting supply [3][4]. Summary by Sections Pharmaceutical Raw Materials - Chemical product prices have risen significantly due to international oil price increases and high overseas energy costs, impacting the cost structure of downstream industries [2][12]. - The supply side is under pressure due to previous expansions in production capacity from 2020 to 2022, which may lead to gradual price transmission [14][15]. - Demand is expected to improve as customer inventory levels are low, indicating that any price increases could be sustained [19][22]. - Recommended stocks in this sector include Puluo Pharmaceutical, Aorite, Tianyu Co., Huahai Pharmaceutical, and Jiuzhou Pharmaceutical [6][22]. Medical Consumables - The nitrile gloves market is dominated by production in China and Malaysia, with significant market share and high manufacturing barriers, making it difficult for new entrants to scale quickly [3][4]. - The price of nitrile gloves is currently at historical lows, but geopolitical tensions are expected to drive raw material prices up, leading to a potential recovery in glove prices [3][4]. - Domestic leading companies are extending their supply chains upstream into nitrile latex production, enhancing their cost control and supply chain advantages during periods of rising raw material prices [4][6]. - Recommended stocks in this sector include YK Medical, Blue Sail Medical, and Zhonghong Medical [6][22].

Investment Rating - The report suggests a focus on the pharmaceutical raw materials and medical consumables sectors, particularly highlighting the potential for price increases in raw materials due to rising costs in the chemical industry and the supply chain advantages of leading companies in the medical nitrile gloves market [6][22]. Core Insights - The pharmaceutical raw materials sector is expected to see price increases driven by rising costs of upstream raw materials, with downstream products likely to benefit from improved profit elasticity as customer inventory levels remain low [2][19]. - The medical consumables sector, particularly the nitrile gloves market, is characterized by high barriers to entry and stable supply dynamics, with potential for price recovery as raw material costs rise and supply-demand conditions improve [3][4][48]. Summary by Sections Pharmaceutical Raw Materials - The chemical products have seen significant price increases due to rising international oil prices and high overseas energy costs, which are expected to drive up costs in downstream industries such as pharmaceutical intermediates and raw materials [2][12]. - The supply side has experienced pressure due to concentrated capacity expansion from 2020 to 2022, leading to a gradual transmission of cost pressures downstream [14][15]. - Demand-side factors indicate that customer inventory levels have been low for an extended period, suggesting that any price increases will likely be sustainable [19][22]. Medical Consumables - The nitrile gloves market is dominated by production in China and Malaysia, with significant barriers to entry due to the need for long-term investment in production capabilities and technology [3][4]. - The price of medical nitrile gloves is currently at historical lows, but is expected to rise due to geopolitical tensions affecting raw material prices and improving supply-demand dynamics [3][4][48]. - Leading companies in this sector are extending their operations upstream into nitrile latex production, which enhances their supply chain advantages and cost control capabilities [4][61]. - The report highlights that the global demand for disposable gloves is expected to stabilize and grow, driven by increased health awareness and regulatory standards in the medical industry [63].

Group 1: Financial Performance - In 2025, the company achieved a revenue of 9.784 billion yuan, a year-on-year decrease of 18.62% [3] - The net profit attributable to shareholders was 891 million yuan, down 13.62% year-on-year; the net profit after deducting non-recurring gains and losses was 769 million yuan, a decrease of 21.86% [3] - The raw material drug segment reported a revenue of 6.165 billion yuan, a decline of 28.74% year-on-year, with a gross profit of 834 million yuan, down 35.59% [5] - The pharmaceutical segment generated a revenue of 1.155 billion yuan, a decrease of 18.42%, with a gross profit of 708 million yuan, down 7.3% [6] Group 2: CDMO Business Growth - The CDMO segment achieved a revenue of 2.198 billion yuan, a year-on-year increase of 16.66%, with a gross profit of 994 million yuan, up 28.54% [3] - The gross margin for the CDMO segment was 45.24%, an increase of 4.18 percentage points year-on-year [3] - The number of ongoing CDMO projects reached 1,311, a 32% increase year-on-year, with 398 commercialized projects, up 12% [4] - The company has signed confidentiality agreements with 713 innovative drug companies, an increase of 141 from the previous year [4] Group 3: R&D and Innovation - R&D expenditure for 2025 was 659 million yuan, a year-on-year increase of 2.79% [7] - The company has 1,326 R&D personnel, with 55 holding PhDs and 559 holding master's degrees, making up nearly 20% of the workforce [7] - The company plans to maintain a steady annual increase of 5% to 8% in R&D investment to support CDMO business growth and new technology fields [12] Group 4: Market Conditions and Challenges - The pharmaceutical industry environment remains challenging, heavily influenced by industry policies, particularly centralized procurement [3] - The overall raw material drug industry is in a downturn, with significant price pressures affecting sales [5] - The company anticipates continued improvement in the raw material drug business in 2026 after a challenging 2025 [6] Group 5: Future Outlook - The company expects to deliver over 6 billion yuan in commercialized orders within the next three years for the CDMO business [11] - The company aims to scale its medical beauty and cosmetic raw materials business to 1 billion yuan within three to five years [10] - The company plans to balance shareholder returns with the funding needs for CDMO business expansion, with over 92% of profits allocated for dividends in 2025 [15]

Core Viewpoint - The global pharmaceutical supply chain is facing significant challenges due to rare earth controls and logistics disruptions from geopolitical conflicts, highlighting the need for a shift from efficiency-focused strategies to safety and controllability in supply chains [2][6][26]. Group 1: Supply Chain Dynamics - The traditional model of minimizing costs and inventory in the pharmaceutical industry is becoming increasingly vulnerable due to disruptions in raw material supply and international logistics [2][6]. - High-end medical equipment and advanced nuclear medicines rely heavily on critical materials and efficient transportation, making timely production and delivery crucial [2][6]. - The current geopolitical climate has exposed the fragility of supply chains that prioritize cost over stability, prompting a reevaluation of strategies in the pharmaceutical sector [6][26]. Group 2: Role of China in Supply Chain Reconstruction - China’s pharmaceutical industry is characterized by a comprehensive supply chain that includes everything from raw materials to finished products, positioning it as a key player in the global market [8][11]. - The ability to provide stable manufacturing and supply capabilities, along with increasing innovation in drug development, enhances China's role in the pharmaceutical supply chain [11][12]. - China's advantages in raw material production and its capacity to adapt to external disruptions make it a critical component in maintaining supply chain stability [21][23]. Group 3: Policy and Industry Focus - Recent policy shifts in China are aimed at elevating the pharmaceutical sector to a "pillar industry," emphasizing the need for innovation and international competitiveness [12][14]. - The focus on innovative drugs and raw materials reflects a strategic direction to enhance both the upper and lower ends of the pharmaceutical supply chain [14][19]. - The integration of artificial intelligence in drug development is expected to shorten research cycles and reduce costs, further driving innovation in the pharmaceutical industry [18]. Group 4: Future Outlook - The pharmaceutical industry is transitioning from a focus on cost and speed to one that values stability, comprehensiveness, and continuous innovation [26]. - China's complete industrial chain provides a significant advantage in ensuring supply stability, while its growing innovation capabilities allow it to participate in higher-value segments of the market [27].

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside in the stock price [4]. Core Insights - The company has launched a stock incentive plan for its CDMO business core management and technical staff, which is expected to drive growth. The plan involves granting 7.597 million stock options at a price of 13.38 RMB, with performance targets set for net profit growth from 2026 to 2029 [4]. - The CDMO business has become the largest revenue contributor, with a revenue of 1.69 billion RMB in the first three quarters of 2025, representing a year-over-year growth of 20%. The gross margin for this segment is 44.5%, up by 3.7 percentage points [7]. - The company anticipates a recovery in overall performance, with expected net profits of 909 million RMB in 2025, 1.052 billion RMB in 2026, and 1.233 billion RMB in 2027, reflecting a year-over-year growth of 15.76% and 17.20% in the following years [6][7]. Financial Summary - The company’s projected net profit for 2025 is 909 million RMB, with an EPS of 0.78 RMB, and a P/E ratio of 22.91. For 2026, the net profit is expected to rise to 1.052 billion RMB, with an EPS of 0.91 RMB and a P/E ratio of 19.79. By 2027, the net profit is projected to reach 1.233 billion RMB, with an EPS of 1.06 RMB and a P/E ratio of 16.89 [6][10]. - The company’s revenue is expected to increase from 10.472 billion RMB in 2025 to 11.347 billion RMB in 2026, and further to 12.047 billion RMB in 2027 [10].

Investment Rating - The report upgrades the investment rating of the company to "Buy" [4] Core Insights - The company has launched a stock incentive plan for key management and technical personnel in its CDMO business, which is expected to drive growth. The plan involves granting 7.597 million stock options, representing approximately 0.66% of the total share capital, with a grant price of 13.38 RMB per share [4] - The CDMO business has become the largest revenue contributor, with a revenue of 1.69 billion RMB in the first three quarters of 2025, showing a year-over-year growth of 20%. The gross margin for this segment is 44.5%, an increase of 3.7 percentage points [7] - The company anticipates a recovery in performance, with projected net profits of 909 million RMB, 1.052 billion RMB, and 1.233 billion RMB for 2025, 2026, and 2027 respectively, reflecting a year-over-year growth of -11.9%, +15.8%, and +17.2% [6][7] Financial Summary - The company's projected net profit for 2025 is 909 million RMB, with an EPS of 0.78 RMB, and a P/E ratio of 22.91 [6] - For 2026, the net profit is expected to rise to 1.052 billion RMB, with an EPS of 0.91 RMB, and a P/E ratio of 19.79 [6] - By 2027, the net profit is projected to reach 1.233 billion RMB, with an EPS of 1.06 RMB, and a P/E ratio of 16.89 [6]